Comment on CMS-2026-1255-0001

Summary: Bristol Myers Squibb supports the proposed rule to extend electronic prior authorization to prescription medicines and improve transparency and decision timeframes. The company also advocates for stricter oversight of step therapy, requesting specific exceptions for patients with stable conditions, prior treatment failures, or rapidly progressive diseases.